Sector Investing

[ReturntoSender]

AMGN and SEPR are two biotechs that have fallen out of favor. What I know about both companies is that future earnings growth is being called into question. That said we have here two biotechs that profitable members of the NASDAQ 100. If we applied the same pricipals that seem to lead to profits for those who follow the dogs of the dow theory then we might expect AMGN and SEPR to be leaders next year.









Analysts projections suggest that both stocks are undervalued:

http://www.smartmoney.com/pricecheck/index.cfm?story=worksheet&symbol=AMGN&nav=pc_snaps

http://www.smartmoney.com/eqsnaps/index.cfm?story=earningsforecast&symbol=AMGN

http://www.smartmoney.com/pricecheck/index.cfm?story=worksheet&symbol=SEPR&nav=pc_snaps

http://www.smartmoney.com/eqsnaps/index.cfm?story=earningsforecast&symbol=SEPR

http://www.smartmoney.com/eqsnaps/index.cfm?story=earningsforecast&symbol=SEPR

http://finance.yahoo.com/q?s=AMGN+SEPR&d=t

RtS